WO2018212588A1 - Composition contenant un extrait de camellia sinensis - Google Patents

Composition contenant un extrait de camellia sinensis Download PDF

Info

Publication number
WO2018212588A1
WO2018212588A1 PCT/KR2018/005605 KR2018005605W WO2018212588A1 WO 2018212588 A1 WO2018212588 A1 WO 2018212588A1 KR 2018005605 W KR2018005605 W KR 2018005605W WO 2018212588 A1 WO2018212588 A1 WO 2018212588A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
gallate
composition
methyl
epigallocatechin
Prior art date
Application number
PCT/KR2018/005605
Other languages
English (en)
Korean (ko)
Inventor
황경환
박준성
박녹현
이민석
유주
Original Assignee
주식회사 아모레퍼시픽
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 아모레퍼시픽 filed Critical 주식회사 아모레퍼시픽
Priority to CN201880032982.9A priority Critical patent/CN111050783A/zh
Priority to MYPI2019006749A priority patent/MY197901A/en
Publication of WO2018212588A1 publication Critical patent/WO2018212588A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K15/00—Anti-oxidant compositions; Compositions inhibiting chemical change
    • C09K15/04—Anti-oxidant compositions; Compositions inhibiting chemical change containing organic compounds
    • C09K15/06—Anti-oxidant compositions; Compositions inhibiting chemical change containing organic compounds containing oxygen
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K15/00—Anti-oxidant compositions; Compositions inhibiting chemical change
    • C09K15/34—Anti-oxidant compositions; Compositions inhibiting chemical change containing plant or animal materials of unknown composition
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/302—Foods, ingredients or supplements having a functional effect on health having a modulating effect on age
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10—Preparation or pretreatment of starting material
    • A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10—Preparation or pretreatment of starting material
    • A61K2236/17—Preparation or pretreatment of starting material involving drying, e.g. sun-drying or wilting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/522—Antioxidants; Radical scavengers

Definitions

  • the present invention is a composition containing an extract of a tea tree, preferably an extract of a new type of tea tree (Jangwon No. 3), more specifically epigallocatechin-3- O- (3- O -methyl) gallate (epigallocatechin-
  • the present invention relates to a composition containing an extract of Camellia sinensis , which contains a high content of 3-O- (3-O-methyl) gallate; EGCG3 ”Me; 3” -O- Me-EGCG) as an active ingredient.
  • Human skin is changed by a number of internal and external factors as it ages. That is, internally, the secretion of various hormones that regulate metabolism decreases, and the function of immune cells and the activity of cells decreases, thereby reducing the biosynthesis of immune proteins and constituent proteins necessary for living organisms. Due to the increase in the amount of ultraviolet rays that reach the surface of the sun's rays and intensifying environmental pollution, free radicals and active oxygen radicals increase, thereby reducing the thickness of the skin, increasing wrinkles, and reducing elasticity. The color of the skin becomes dull, skin problems frequently occur, and there are various changes such as blemishes, freckles, and black mushrooms.
  • cyclooxygenase-2 (Cox-2, cyclooxygenase), an enzyme that produces proinflammatory cytokine, which is known to cause inflammation in most cells constituting the skin, due to aging or ultraviolet rays.
  • MMP matrix metalloproteinase
  • iNOS inducible nitric oxide synthase
  • the biosynthesis of the substrate material is reduced due to the decrease of cellular activity and micro-inflammatory due to the naturally occurring endogenous aging, the external factors such as the increase of stress caused by various harmful environments and the increase of free radical species by the sun's rays. Degradation and degeneration are accelerated by this, resulting in the destruction and thinning of the skin matrix, resulting in various symptoms of skin aging. Therefore, a lot of research is being conducted on the active ingredient that can prevent and improve the phenomenon of aging.
  • SOD superoxide dismutase
  • Free radicals such as superoxide, are produced in the body by external stress, ultraviolet rays, smoking, drugs, free radicals, etc., and have non-selective and irreversible destruction against cellular components such as lipids, proteins, sugars, and nucleic acids (eg, DNA). By doing so, it is known to cause various diseases such as cancer, stroke, Parkinson's disease, heart disease, ischemia, arteriosclerosis, skin disease, digestive disease, inflammation, rheumatism, autoimmune disease, as well as aging. In this way, free radicals cause various functional disorders due to oxidative destruction of cells, thereby causing aging and disease.
  • diseases such as cancer, stroke, Parkinson's disease, heart disease, ischemia, arteriosclerosis, skin disease, digestive disease, inflammation, rheumatism, autoimmune disease, as well as aging.
  • free radicals cause various functional disorders due to oxidative destruction of cells, thereby causing aging and disease.
  • the tea tree is an evergreen belonging to the family Camellia (Family: Theaceae ), and the scientific name is Camellia sinensis .
  • the cultivated tea tree can be divided into varieties ( var. Assamica ) and Chinese varieties ( var.sinesis ), which have broad leaf characteristics and are distributed in tropical and subtropical areas such as India and Sri Lanka. It is widely used as a dragon, and Chinese species have lobular characteristics, and are distributed in temperate regions such as Korea, China, and Japan, and have strong cold resistance.
  • Korean native tea trees are mainly classified as Chinese species.
  • the tea tree is a subtropical crop with an average annual temperature of 14 ⁇ 16 °C.
  • Low temperature is a limiting factor for the growth of tea trees, and even after a one-hour pass at -15 °C, the leaves will die, and if it exceeds 40 °C, a high temperature disorder occurs.
  • the minimum amount of precipitation required to grow the tea tree is at least 1,300 mm, but for optimal tea cultivation requires more than 1,500 mm of precipitation per year.
  • the tea tree is reported to have been planted around China in Jirisan during the late Silla 828.
  • Native plants are grown in the southern part of Korea, which is below the cultivation limit of 13 °C, and are grown in Jeonbuk, Jeonnam, Gyeongnam, and Jeju.
  • Tea is characterized by a higher content of nitrogen compounds, polyphenols, sugars, organic acids, vitamins and minerals than other beverages.Amino acids are closely related to the taste of tea and certain amino acids such as deanine affect the quality. It is also known that the components of these amino acids correlate with the price of the product. The total nitrogen content of tea leaves is traditionally an important factor in determining the quality of tea along with amino acids.
  • Tea protein is hardly eluted due to coagulation with tannin or coagulation by heating in the manufacturing process, but amino acids and amides are water soluble and are eluted to greatly influence the taste of tea.
  • Tea has been used since ancient times as well as various pharmacological action. In recent years, research on this has been actively conducted, focusing on the functionality of the car. Tea is particularly rich in polyphenols, and most of the polyphenols in tea are flavonoids known as catechin compounds.
  • Deanine is a high component of about 40 to 60% by weight of the total free amino acids of green tea, which is rarely found in other crops and is contained only in the leaves of tea trees. Deanin has a great influence on the taste of tea, and it is correlated with the quality of tea along with total free amino acids and total nitrogen, and is used as an important indicator for quality evaluation along with sensory evaluation. It is evaluated as a factor.
  • the tea tree is a corrosive crop in which the pollination is made between individuals with different genotypes, and the variation between individuals is severe. Therefore, conventionally grown cultivated tea is not a single cultivar, but a hybrid that has been descended for a long time by sexual reproduction, and the genetic characteristics of each tea tree are all different. Harvesting time, growth rate, leaf shape and color, composition, disease resistance, and cold resistance And many other characteristics. These conventional species have high genetic value for breeding, but it is urgent to develop tea varieties that can maintain a uniform quality while showing excellent functionality even after multiple breeding.
  • the breeding method of the new tea tree varieties (named “Changwon No. 2”) having a high amino acid and deanin content has been developed. All of these breeding methods are characterized by selecting tea trees having the desired characteristics among conventional tea trees, and abundantly breeding by cutting to reproduce excellent genetic traits without mutation.
  • tea tree varieties are difficult to improve because they are genetically very sparse because they have a long breeding period like other young plants.
  • efficacy of the tea leaf extract obtained from these tea trees has not been specifically identified.
  • the present inventors analyzed the components of the extract obtained from the tea leaves of the new tea tree varieties (Changwon No. 3) produced through the breeding method and the cultivation method of the new tea tree and its efficacy and applied to pharmaceuticals, cosmetics, food, etc. , a tea extract, preferably a new variety of tea (manor third) extract of 3-epi catechins in particular go O - (3- O - methyl) gallate (epigallocatechin-3-O- (3 -O-methyl ) gallate; EGCG3 ”Me; 3” -O- Me-EGCG), and found to be excellent in antioxidant, anti-inflammatory, anti-aging and anti-cancer effects, and completed the present invention.
  • a tea extract preferably a new variety of tea (manor third) extract of 3-epi catechins in particular go O - (3- O - methyl) gallate (epigallocatechin-3-O- (3 -O-methyl ) gallate; EGCG3 ”Me; 3
  • An object of the present invention the epi catechins to go in accordance with the present invention -3- O - (3- O - methyl) gallate (epigallocatechin-3-O- (3 -O-methyl) gallate; EGCG3 "Me;3" It is to provide a composition containing an extract of a tea tree containing a high content of O -Me-EGCG, preferably an extract of a new tea tree (Changwon No. 3) as an active ingredient.
  • the extract of the tea tree containing a high content of epigallocatechin-3- O- (3- O -methyl) gallate according to the present invention preferably of a new type of tea tree (Changwon No. 3)
  • the present invention provides a pharmaceutical composition, a cosmetic composition or a nutraceutical composition containing the extract as an active ingredient and having antioxidant, anti-inflammatory, anti-aging and anticancer uses.
  • the present invention is a composition containing an extract of tea tree containing epigallocatechin-3- O- (3- O -methyl) gallate in a high content, preferably an extract of a new type of tea tree (Jangwon No. 3) as an active ingredient. To provide.
  • the present invention also contains an extract of a tea tree containing epigallocatechin-3- O- (3- O -methyl) gallate in a high content, preferably an extract of a new tea tree species (Changwon No. 3) as an active ingredient.
  • an antioxidant pharmaceutical composition, cosmetic composition or health functional food composition preferably an extract of a tea tree species (Changwon No. 3) as an active ingredient.
  • the present invention also contains an extract of a tea tree containing epigallocatechin-3- O- (3- O -methyl) gallate in a high content, preferably an extract of a new tea tree species (Changwon No. 3) as an active ingredient.
  • an extract of a tea tree containing epigallocatechin-3- O- (3- O -methyl) gallate in a high content preferably an extract of a new tea tree species (Changwon No. 3) as an active ingredient.
  • the present invention also contains an extract of a tea tree containing epigallocatechin-3- O- (3- O -methyl) gallate in a high content, preferably an extract of a new tea tree species (Changwon No. 3) as an active ingredient.
  • an extract of a tea tree containing epigallocatechin-3- O- (3- O -methyl) gallate in a high content preferably an extract of a new tea tree species (Changwon No. 3) as an active ingredient.
  • the present invention also contains an extract of a tea tree containing epigallocatechin-3- O- (3- O -methyl) gallate in a high content, preferably an extract of a new tea tree species (Changwon No. 3) as an active ingredient.
  • an anticancer pharmaceutical composition, cosmetic composition or health functional food composition preferably an extract of a tea tree species (Changwon No. 3) as an active ingredient.
  • the present invention also provides an extract of a tea tree, preferably a new type of tea tree, comprising a high content of epigallocatechin-3-O- (3-O-methyl) gallate in the manufacture of an antioxidant pharmaceutical composition or medicament.
  • an extract of (Changwon 3) as an antioxidant is provided.
  • the present invention also provides an extract of a tea tree containing a high content of epigallocatechin-3-O- (3-O-methyl) gallate in the production of an antioxidant cosmetic composition, preferably a new kind of tea tree (Changwon 3 The use of the extract of the present invention) as an antioxidant.
  • the present invention also provides an extract of a tea tree, preferably a new type of tea tree, comprising a high content of epigallocatechin-3-O- (3-O-methyl) gallate in the manufacture of an antioxidant functional food composition.
  • the present invention also provides an extract of a tea tree, comprising a high content of epigallocatechin-3-O- (3-O-methyl) gallate in the manufacture of a pharmaceutical composition or medicament for anti-inflammatory or anti-inflammatory, preferably Provides the use of an extract of tea tree new varieties (Jangwon 3) as an anti-inflammatory or anti-inflammatory agent.
  • the present invention is also an extract of a tea tree, preferably a new kind of tea tree, which comprises a high content of epigallocatechin-3-O- (3-O-methyl) gallate in the preparation of an anti-inflammatory or anti-inflammatory cosmetic composition.
  • the use of the extract of (Changwon 3) as an anti-inflammatory or anti-inflammatory agent is provided.
  • the present invention also provides an extract of a tea tree, comprising a high content of epigallocatechin-3-O- (3-O-methyl) gallate, in the preparation of an anti-inflammatory or anti-inflammatory health food composition.
  • an anti-inflammatory or anti-inflammatory agent of an extract of a new tea tree species (Changwon No. 3).
  • the present invention also provides an extract of a tea tree, preferably a new type of tea tree, comprising a high content of epigallocatechin-3-O- (3-O-methyl) gallate in the manufacture of an anti-aging pharmaceutical composition or medicament.
  • the use of the extract of (Changwon 3) as an anti-aging agent is provided.
  • the present invention also provides an extract of a tea tree containing a high content of epigallocatechin-3-O- (3-O-methyl) gallate in the preparation of an anti-aging cosmetic composition, preferably a new kind of tea tree (Jangwon 3 The use of the extract of the present invention) as an anti-aging agent.
  • the present invention also provides an extract of a tea tree containing a high content of epigallocatechin-3-O- (3-O-methyl) gallate in the manufacture of an anti-aging dietary supplement composition, preferably a new kind of tea tree ( The use of the extract of Jangwon 3) as an anti-aging agent.
  • the present invention is also an extract of a tea tree, preferably a new type of tea tree, comprising a high content of epigallocatechin-3-O- (3-O-methyl) gallate in the manufacture of a pharmaceutical composition or medicine for anticancer
  • the use of the extract of (Changwon 3) as an anticancer agent is provided.
  • the present invention also provides an extract of a tea tree containing a high content of epigallocatechin-3-O- (3-O-methyl) gallate in the manufacture of an anticancer cosmetic composition, preferably a new kind of tea tree (Changwon 3
  • An anticancer agent is provided as an anticancer agent.
  • the present invention is also an extract of a tea tree containing a high content of epigallocatechin-3-O- (3-O-methyl) gallate in the manufacture of a dietary supplement composition for anticancer, preferably a new kind of tea tree ( The use of the extract of Jangwon 3) as an anticancer agent.
  • composition containing the extract of the tea tree containing epigallocatechin-3- O- (3- O -methyl) gallate in high content according to the present invention as an active ingredient has an antioxidant effect and cola due to free radical scavenging and inhibition. It has an excellent inhibitory ability to generate geneases to prevent skin aging, and it has anti-inflammatory effect by inhibiting the expression and secretion of inflammatory factors such as prostaglandin and IL-8 in skin cells, and anti-cancer effect against cancer cell lines derived from various tissues. great.
  • Figure 1 shows the elite line selection of the collected green tea tree germplasm (germplasm).
  • Figure 2 shows the single cutting propagation of a single tea tree of the selected green tea tree.
  • Figure 3 shows a new varieties of tea tree (Mountain 3).
  • Figure 4 shows the superoxide anion scavenging activity of the new tea extract (Changwon No. 3).
  • Figure 5 shows the hydroxyl radical (hydroxyl radical) scavenging activity of a new tea (Jangwon No. 3) extract.
  • the new tea varieties (New Cultivar of Camellia sinensis) is a new tea varieties (Changwon No. 3) (seed accession number: KCTC (Korean Collection for Type Cultures) 12213BP (2012.5.14); No.] of the tea leaf extract, after analyzing the components of the extract, the total content of the catechin is 41.1% by weight of the extract of the new tea (Changwon No. 3) tea leaves, Yabugi is a general tea tree introduced varieties Leaf extract (28.1% by weight), kanayamidori leaf extract (26.7% by weight), utagamidori leaf extract (26.4% by weight) was higher than the extract.
  • new varieties of tea (manor third) extract of catechin to go epi -3- O - (3- O - methyl) gallate epigallocatechin-3-O- (3 -O-methyl) gallate; EGCG3 "Me; 3 ” -O- Me-EGCG
  • EGCG3 "Me; 3 ” -O- Me-EGCG was contained in an amount of 2.5% by weight, and was found to contain 10 times or more higher than the general tea tree introduced varieties (see Example 1 and Test Example 1, Table 6).
  • the extract of the new tea tree (Changwon No. 3) leaf was Yabu
  • the total content of catechin was higher than the extract.
  • the content of 3 ” -O- Me-EGCG) in the extracts of the leaves of the new tea tree (Changwon No. 3) was 4.7 mg ⁇ g -1 , 3.6 in green tea, oolong tea (semi-fermented tea) and black tea (fermented tea), respectively. mg.g -1 and 1.94 mg.g -1 .
  • the antioxidant effect of the extract of tea tree new varieties (Jangwon No. 3) according to the present invention was confirmed.
  • Table 8 (i) new tea tree varieties (Changwon 3) in the DPPH (1,1-diphenyl-2-picrylhydrazyl; 1,1-diphenyl-2-picryl hydrazyl) test Extract (Example 1) showed a similar antioxidant effect compared to the ascorbic acid (vitamin C), an antioxidant used as a positive control, and extracts Yabugida, Kanayamidori and Yutagami-dori extracts of general tea trees of Comparative Examples 1 to 3 Compared with, it showed significantly higher antioxidant efficacy, and (ii) In the superoxide anion scavenging activity test, the new tea extract (Changwon No.
  • the anti-aging effect of the extract of the new tea varieties (Changwon No. 3) according to the present invention was confirmed through the ability to inhibit the production of collagenase.
  • Table 9 the lower the expression level of collagenase, the higher the expression inhibiting ability of collagenase, less degradation of collagen in the skin, inhibiting the decrease in skin elasticity, and the amount of wrinkles produced decreased.
  • the extract of the new tea tree (Changwon No. 3) according to the present invention (Example 1) effectively inhibited the expression of collagenase in vitro , and inhibited the expression of collagenase than tocopherol used as a positive control. This excellence could be confirmed.
  • the extract of Tea tree new varieties (Changwon No. 3) according to the present invention is more to the expression of collagenase than the general tea tree introduced varieties Yabugida, Kanayami-dori and Yutagami-dori extracts of Comparative Examples 1 to 3 It was confirmed that the effect of inhibiting collagen breakdown in the skin by effectively inhibiting the skin elasticity enhancing effect and wrinkle reduction effect is excellent (see Test Example 3).
  • the anti-inflammatory effect of the extract of the new tea tree (Changwon No. 3) according to the present invention is confirmed through the inhibitory effect of the production of prostaglandins and the inhibitory effect of the production of Interleukin-8 (IL-8) It was.
  • the extract (Example 1) of the new tea tree (Changwon No. 3) according to the present invention was found to have a very high inhibitory effect of the production of prostaglandins, as in the control group treated with aspirin, compared to It was found that the effect of inhibiting prostaglandin production was significantly higher than that of Yabugida, Kanayami-dori, or Yutagami-dori extracts.
  • the extract (Example 1) of the new tea tree varieties (Changwon No. 3) according to the present invention has a very high inhibitory effect on the secretion of IL-8 increased by PGSA, an inflammation-inducing stimulant. It was found that the secretion of IL-8 was significantly reduced and suppressed compared to the general tea tree-introduced varieties Yabugida, Kanayami-dori or Yutagami-dori extracts of Comparative Examples 1 to 3 (see Test Example 4).
  • the anticancer effect of the extract of the new tea tree varieties (Changwon No. 3) according to the present invention was confirmed through the cancer cell proliferation inhibitory effect.
  • Table 12 when (i) a new tea tree (Changwon No. 3) extract was treated to each cancer cell line at a concentration of 100 ⁇ g ⁇ mL ⁇ 1 , the cancer cell proliferation rate was 50% or less in all cancer cell lines. (Survival rate); When a new tea tree (Changwon No.
  • Lung cancer cell line (A549) showed cancer cell proliferation rate when 3 ” -O- Me-EGCG was treated at concentrations of 50 ⁇ g mL- 1 , 100 ⁇ g mL- 1 and 200 ⁇ g mL- 1 . 41.0%, 20.0%, and 16.0%, respectively, and lung cancer cell line (A549) inhibited cancer cell proliferation higher than prostate cancer cell line (LNCaP) and breast cancer cell line (MCF-7). It exhibited the features (see Test Example 5).
  • the sensory evaluation of the polysaccharide containing the extract of a new type of tea tree (Changwon No. 3) according to the present invention was performed.
  • the new variety of tea tree (Changwon No. 3) had higher palatability in both semi-fermented tea, fermented tea, and post-fermented tea than Yabugida and Okumi-dori. Was evaluated (see Test Example 6).
  • the invention in one aspect, to go epi catechins -3- O - (3- O - methyl) gallate (epigallocatechin-3-O- (3 -O-methyl) gallate; EGCG3 "Me;3" - It relates to a composition containing as an active ingredient the extract of Camellia sinensis containing a high content of O- Me-EGCG).
  • the extract of the tea tree may be characterized in that the extract of the tea tree new varieties (Changwon No. 3), but is not limited thereto.
  • the composition may be an antioxidant, anti-inflammatory, anti-aging and anticancer pharmaceutical composition, cosmetic composition or health functional food composition, but is not limited thereto.
  • the content of epigallocatechin-3- O- (3- O -methyl) gallate contained in the extract of the tea tree is 1.25% by weight or more, preferably 1.25 to 8.00% by weight, more preferably 1.88 to 7.00% by weight %, Most preferably 2.25 to 6.00% by weight.
  • the invention from another point of view, as the epi catechins go -3- O - (3- O - methyl) gallate (epigallocatechin-3-O- (3 -O-methyl) gallate; EGCG3 "Me;3" - O -
  • pharmaceutical composition, cosmetic composition or health functional food composition for antioxidant containing as an active ingredient the extract of the tea tree ( Camellia sinensis ) containing a high content of Me-EGCG),
  • the content of epigallocatechin-3- O- (3- O -methyl) gallate contained in the extract of the tea tree is 1.25% by weight or more, preferably 1.25 to 8.00% by weight, more preferably 1.88 to 7.00% by weight %, Most preferably 2.25 to 6.00% by weight.
  • the epi-catechins to go -3- O - (3- O - methyl) gallate epigallocatechin-3-O- (3 -O-methyl) gallate; EGCG3 "Me;3" - O
  • the content of epigallocatechin-3- O- (3- O -methyl) gallate contained in the extract of the tea tree is 1.25% by weight or more, preferably 1.25 to 8.00% by weight, more preferably 1.88 to 7.00% by weight %, Most preferably 2.25 to 6.00% by weight.
  • the epi-catechins to go -3- O - (3- O - methyl) gallate epigallocatechin-3-O- (3 -O-methyl) gallate; EGCG3 "Me;3" - O
  • cosmetic composition or health functional food composition containing the extract of the tea tree ( Camellia sinensis ) containing a high content of -Me-EGCG as an active ingredient,
  • the content of epigallocatechin-3- O- (3- O -methyl) gallate contained in the extract of the tea tree is 1.25% by weight or more, preferably 1.25 to 8.00% by weight, more preferably 1.88 to 7.00% by weight %, Most preferably 2.25 to 6.00% by weight.
  • the epi-catechins to go -3- O - (3- O - methyl) gallate epigallocatechin-3-O- (3 -O-methyl) gallate; EGCG3 "Me;3" - O
  • anti-cancer pharmaceutical composition, cosmetic composition or health functional food composition containing as an active ingredient an extract of tea tree containing Camellia sinensis with a high content of -Me-EGCG
  • the content of epigallocatechin-3- O- (3- O -methyl) gallate contained in the extract of the tea tree is 1.25% by weight or more, preferably 1.25 to 8.00% by weight, more preferably 1.88 to 7.00% by weight %, Most preferably 2.25 to 6.00% by weight.
  • Tea tree new varieties (Jangwon No. 3) (seed accession number: KCTC (Korean Collection for Type Cultures) 12213BP (2012.5.14)) according to the present invention is supplied from Jangwon.
  • a new type of tea tree (Changwon No. 3) is obtained for the purpose of developing varieties of functional tea trees containing a large amount of catechins, which are excellent in antioxidant, anti-aging, skin whitening, anti-cancer and anti-allergic effects.
  • As a cultivar we conducted a separate breeding method on tea tree genes of Andeok-myeon, Andeok-myeon, Seogwipo-si, collected in 2006, and selected a small number of tea trees with high catechins by evaluation of growth characteristics and component contents.
  • the mating and breeding system was conducted in consideration of quality and quantity.
  • the seedlings were sown in breeding houses for mating livestock, and after the formalization of this pavement, the second selection was carried out in 2010 through component analysis and plant characteristics evaluation. Crop characteristics were measured according to the International Union for the Protection of New Varieties of Plants (UPOV) of the Korean National Species (see Preparation Example below).
  • the extract of the tea tree may be at least one extract selected from the group consisting of flowers, leaves, fruits, stems and roots of the tea tree, but is not limited thereto, preferably the extract of the tea tree leaves to be.
  • the tea tree according to the present invention in particular, has a high catechin content in its leaves, epigallocatechin-3- O ⁇ among the catechins contained in the extract of the tea tree, preferably the extract of the new tea tree (Changwon No. 3).
  • the content of (3- O -methyl) gallate is at least 1.25% by weight, preferably 1.25 to 8.00% by weight, more preferably 1.88 to 7.00% by weight, most preferably 2.25 to 6.00% by weight.
  • the extract of the tea tree is epigallo contained in the tea tree's flowers, leaves, berries, stems or roots depending on the harvest time (harvest season), or the harvesting time (harvest season) of the flower, leaf, fruit, stem or root of the tea tree.
  • the content of catechin-3- O- (3- O -methyl) gallate may vary. For example, 2.50% by weight of the new cultivated tea tree (Changwon No. 3) in May, 4.16% in August, or 5.36% in November by epigallocatechin-3- O- (3- O -methyl ) Tea leaf extract containing gallate can be obtained.
  • epi catechins go -3- O - (3- O - methyl) acrylate go are O - as EGCG with a methylated form , 3 ” -O- Me-EGCG or EGCG3” Me.
  • the tea tree according to the present invention has a high catechin content in its leaves, the extract of the tea tree, preferably the extract of the new tea tree (Changwon No. 3) is gallocatechin (gallocatechin (GC), epigallocatechin ( epigallocatechin (EGC), catechin (C), epicatechin (EC), epigallocatechin gallate (EGCG), gallocatechin gallate (GCG), epicatechin gallate (Epicatechin gallate) Eight catechins of ECG) and catechin gallate (CG) are contained in an amount of 20.55 to 82.2 wt%, preferably 30.8 to 61.65 wt%, more preferably 37 to 51.38 wt%.
  • the extract of the tea tree preferably the extract of the new tea tree (Changwon No. 3) may be characterized by containing 0.01 to 20% by weight relative to the total weight of the composition.
  • the extract of the tea tree preferably the extract of the new type of tea tree (Changwon No. 3) is contained less than 0.01% by weight, anti-oxidant effect, anti-inflammatory effect, anti-aging effect, and anti-cancer effect can not be expected
  • extract of tea tree preferably When the content of the extract of tea tree new varieties (Changwon No. 3) exceeds 20% by weight, skin irritation due to cytotoxicity may be concerned.
  • Tea tree new varieties (Jangwon No. 3) according to the present invention, the step of selecting a tea tree having the characteristics of the following (1) to (5) in the conventional tea tree; Harvesting the selected tea tree when the base of the stem which has not harvested the first tea begins to harden; It is obtained by the breeding method of a new type of tea tree, including the step of inserting into 1 section and 2 sections 2 leaves 1 and obtaining a new tea tree breeding by the asexual propagation method by cutting.
  • the selected tea tree is characterized by having the following characteristics (1) to (5):
  • 1 of the tea extract (e.g., the extract of the tea leaves) to epi go of the catechins contained in the catechin -3- O - (3- O - methyl) gallate is 1.25% by weight or more, preferably 1.25 to 8.00% by weight, more preferably 1.88 to 7.00% by weight, most preferably 2.25 to 6.00% by weight ;
  • leaf width is 37-47 mm, preferably 39-46 mm, more preferably 43-45 mm, most preferably 44.1 mm
  • the leaf length is 85-95 mm, preferably 87-95 mm, more preferably 94 ⁇ 95mm, most preferably be 94.2mm
  • leaf area is 2200 ⁇ 3200mm 2 or 4000 ⁇ 4500mm 2, preferably 2500 ⁇ 2800mm 2 or 4100 ⁇ 4300mm 2, more preferably 4150 ⁇ 4200mm 2, and most preferably from 4154.2 mm 2 ;
  • the lobe is long oval, the mother's hair is medium, and the lobe is green;
  • the new chickpea is 145.0-165.0 mm, preferably 150.0-165.0 mm, more preferably 162.0-164.0 mm, most preferably 163.5 mm, and among white eggs 123.0-143.0 g / 100bud, preferably 128.0- 139.0 g / 100bud, more preferably 136.0-139.0 g / 100bud, most preferably 138.3 g / 100bud; And
  • the selected tea tree may be a tea tree additionally having the following properties (6) to (17).
  • chlorophyll content (soil & plant analyzer development, SPAD) is 58-62;
  • the total amino acid (TFAA) content is at least 3.50 wt%
  • the deanine content is at least 2.20% by weight
  • the total nitrogen content is at least 6.00% by weight
  • the caffeine content is 23.5 mg / g or less
  • the water washing of the eggplant is medium, and the eggplant thickness and eggplant density are medium;
  • the extract of the tea tree is 6.35 to 25.4% by weight, preferably 9.53 to 19.05% by weight, more preferably 11.4 to 15.9% by weight epigallocatechin (EGC), 9.4 to 37.6% by weight, preferably 14.1-28.2 wt%, more preferably 16.9-23.5 wt% epigallocatechin gallate (EGCG) and 2.65-10.6 wt%, preferably 3.98-7.95 wt%, more preferably 4.77-66.63 Weight percent epicatechin gallate (ECG); And
  • the breeding method may further comprise the step of immersing in water for 1 to 2 hours by cutting the lower part of the cut branch obliquely left 2 ⁇ 3 cm from the lowermost leaf after the insertion. .
  • the general cultivation conditions of the conventional tea plant is applied, for example, it can be carried out as follows. Sunscreening should be done immediately after cutting and the transmittance should be around 30 ⁇ 45%. Until the roots are inserted, they are usually absorbed from the lower cut mortar, such as cut flowers, and survive. Approximately 1 month after cutting, root cuttings are excised slightly. After rooting, 50 to 60% of the maximum water is appropriate. Fertilization starts after August and may start from September. Weeding and pest control in seedlings should be carried out with care and sufficient debris after rooting and growth.
  • the tea tree was grown using the cultivation method of the new Camellia sinensis species, characterized by growing the tea tree under the conditions of (1) to (5):
  • the cultivated tea tree is not particularly limited, but is preferably a new tea tree species according to the present invention having the following characteristics (1) to (16):
  • extract of the tea plant new varieties e.g., the extract of the tea leaves
  • epi catechins go of the catechins contained in the -3- O - (3- O - methyl) acrylate
  • EGCG3 Me
  • 3 -O- Me-EGCG
  • EGCG3 Me
  • 3 -O- Me-EGCG
  • chlorophyll content (soil & plant analyzer development, SPAD) is 58-62;
  • the deanine content is at least 2.20% by weight
  • the total nitrogen content is at least 6.00% by weight
  • the caffeine content is 23.5 mg / g or less
  • the leaf width is 37 to 47 mm, preferably 39 to 46 mm, more preferably 43 to 45 mm, most preferably 44.1 mm
  • the leaf length is 85 to 95 mm, preferably 87 to 95 mm, more preferably 94 ⁇ 95mm, most preferably be 94.2mm
  • leaf area is 2200 ⁇ 3200mm 2 or 4000 ⁇ 4500mm 2, preferably 2500 ⁇ 2800mm 2 or 4100 ⁇ 4300mm 2, more preferably 4150 ⁇ 4200mm 2, and most preferably from 4154.2 mm 2 ;
  • the lobes are long oval, the hairs medium and the lobes are green;
  • the new chickpea is 145.0-165.0 mm, preferably 150.0-165.0 mm, more preferably 162.0-164.0 mm, most preferably 163.5 mm, and among white eggs 123.0-143.0 g / 100bud, preferably 128.0- 139.0 g / 100bud, more preferably 136.0-139.0 g / 100bud, most preferably 138.3 g / 100bud;
  • the extract of the new varieties of tea tree is 6.35 to 25.4% by weight, preferably 9.53 to 19.05% by weight, more preferably 11.4 to 15.9% by weight epigallocatechin (EGC), 9.4 to 37.6% by weight, preferably 14.1-28.2% by weight, more preferably 16.9-23.5% by weight epigallocatechin gallate (EGCG) and 2.65-10.6% by weight, preferably 3.98-7.95% by weight, more preferably 4.77- 6.63 wt% epicatechin gallate (ECG); And
  • the total content of catechins of gallate, EGCG), gallocatechin gallate (GCG), epicatechin gallate (ECG) and catechin gallate (CG) is preferably 20.55 to 82.2% by weight, preferably 30.8-61.65 weight%, More preferably, 37-51.38 weight%.
  • the pharmaceutical composition containing the extract of the tea tree is a pharmaceutical, such as preservatives, stabilizers, wetting or emulsifiers, salts and / or buffers for the control of osmotic pressure
  • Adjuvants and other therapeutically valuable substances may further be contained and may be formulated in various oral or parenteral dosage forms in accordance with conventional methods.
  • carrier is defined as a compound that facilitates the addition of a compound into a cell or tissue.
  • DMSO dimethyl sulfoxide
  • carrier facilitates the incorporation of many organic compounds into cells or tissues of an organism.
  • excipient is a substance that is added to make it easier to take medicine or to have a certain color and form when the amount of the main medicine is small in the process of preparation of tablets or pills, such as lactose or starch. do.
  • diot is defined as a compound that not only stabilizes the biologically active form of the compound of interest, but also is diluted in water to dissolve the compound. Salts dissolved in buffer solutions are used as diluents in the art. A commonly used buffer solution is phosphate buffered saline, because it mimics the salt state of human solutions. Because buffer salts can control the pH of a solution at low concentrations, buffer diluents rarely modify the biological activity of a compound.
  • a composition containing an extract of a tea tree preferably an extract of a new tea tree (Changwon No. 3)
  • As a composition it may be administered.
  • Carriers, excipients and diluents that may be included in the pharmaceutical composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose , Methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
  • the oral dosage form may include powders, granules, tablets, capsules, syrups, etc.
  • the parenteral dosage forms may include, for example, injections, drops, ointments, lotions, gels, creams, sprays, suspensions, Formulations such as emulsions, suppositories, and patches may be used, but are not limited thereto.
  • compositions according to an embodiment of the present invention may be administered parenterally, rectally, topically, or transdermally.
  • Pharmaceutical compositions according to one embodiment of the invention may be administered topically to the scalp, for example.
  • the pharmaceutically acceptable dose, ie dosage, of the active ingredient depends on the age, sex, and weight of the subject to be treated, the specific disease or pathology to be treated, the severity of the disease or pathology, the route of administration and the judgment of the prescriber. Will be different. Dosage determination based on these factors is within the level of skill in the art.
  • the dosage is, for example, 1 to several times so as to be administered in an amount of 0.01 to 5000 mg, preferably 0.1 to 2000 mg, more preferably 0.5 to 500 mg, and most preferably 1 to 100 mg per kg of body weight per day. It can be administered in divided, but the dosage is not intended to limit the scope of the invention in any way.
  • compositions suitable for use in the present invention include compositions in which the active ingredients, including extracts of tea tree, preferably extracts of the new tea tree species (Changwon No. 3), are contained in an amount effective to achieve their intended purpose. do. More specifically, a therapeutically effective amount means an amount of a compound effective to prolong the survival of the subject to be treated or to prevent, alleviate or alleviate the symptoms of a disease. Determination of a therapeutically effective amount is within the capabilities of those skilled in the art, in particular in terms of the detailed disclosure provided herein.
  • a therapeutically effective amount for an extract of tea tree, preferably an extract of a new tea tree (Changwon No. 3), and a composition (compounds) containing the same as an active ingredient used in the methods of the present invention is determined initially from cell culture assays.
  • dose can be calculated in an animal model to obtain a range of circulating concentrations that includes an IC 50 (half maximal inhibitory concentration) or EC 50 (half maximal effective concentration) determined in cell culture. Such information can be used to more accurately determine useful doses in humans.
  • Toxicity and therapeutic efficiency of the extracts of the tea tree described herein, preferably the extract of the new tea tree (Changwon No. 3), or compositions (compounds) containing the same as active ingredients, are described, for example, in LD 50 ( To determine lethal dose for 50%), ED 50 (dose with therapeutic effect for 50% of the population), IC 50 (dose with therapeutic inhibitory effect for 50% of the population), in cell culture or laboratory animals. It can be estimated by the table of constraint constraints of. The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio between LD 50 and ED 50 (or IC 50 ). Compounds showing high therapeutic indices are preferred. The data obtained from these cell culture assays can be used to estimate the range of doses used in humans. The dosage or dosage of such compounds is preferably in the range of circulating concentrations including ED 50 (or IC 50 ) in the absence or little toxicity.
  • the formulation of the pharmaceutical composition is preferably any one selected from the group consisting of ointments, lotions, gels, creams, sprays, suspensions, emulsions, and patches.
  • the composition according to the present invention is applied to a pharmaceutical composition, the composition may be formulated in a solid, semi-solid or liquid form by adding a commercially available inorganic or organic carrier using the composition as an active ingredient.
  • the active ingredient of the present invention can be easily formulated, and it can be easily formulated with surfactants, excipients, colorants, spices, stabilizers, preservatives, preservatives, wetting agents, emulsifiers, suspending agents, salts for controlling osmotic pressure and / or Buffers and other commercial auxiliaries can be used as appropriate.
  • the pharmaceutical composition may be a pharmaceutical composition that is effective in treating cancer or a tumor.
  • cancer typically refers to or describes the physiological state of a mammal characterized by unregulated cell growth / proliferation.
  • cancer include, but are not limited to, carcinoma, lymphoma (eg, Hodgkin's and non-Hodgkin's lymphoma), blastoma, sarcoma, and leukemia.
  • cancers include squamous cell cancer, small cell lung cancer, non-small cell lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, peritoneal cancer, hepatocellular cancer, gastrointestinal cancer, pancreatic cancer, glioma, cervical cancer, ovarian cancer, liver cancer, Bladder cancer, hepatocellular cancer, breast cancer, colon cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney cancer, liver cancer, prostate cancer, vulvar cancer, thyroid cancer, liver carcinoma, leukemia and other lymphocytic disorders, and various types of two Contains cervical cancer.
  • the cancer is preferably prostate cancer, lung cancer or breast cancer.
  • the cosmetic composition containing the extract of the tea tree preferably the extract of the new tea tree (Changwon No. 3) is a skin external composition, supple cosmetics, astringent cosmetics, nourishing cosmetics, lotions, eye creams, nutrition creams, massage It may be characterized in that it is formulated into any one selected from the group consisting of cream, cleansing cream, cleansing foam, cleansing water, powder, essence, and pack.
  • composition according to the present invention can be used for fatty substances, organic solvents, solubilizers, thickeners, gelling agents, softeners, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, surfactants, water, ionic or non- With ionic emulsifiers, fillers, metal ion sequestrants, chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, lipid vesicles or any other ingredients commonly used in cosmetics. It may contain adjuvants commonly used in the same cosmetic or dermatology field. Such adjuvants are introduced in amounts generally used in the cosmetic or dermatological arts.
  • the composition of the present invention may contain a skin absorption promoting substance to increase the skin improving effect.
  • carriers useful in cosmetic compositions include, for example, water, acetone, ethanol, ethylene glycol, propylene glycol, butane-1,3-diol, isopropyl myristate, isopropyl palmitate or mineral oil.
  • the carrier may be a solution, a colloidal dispersant, an emulsion (oil-in-water or water-in-oil), a suspension, a cream, a lotion, a gel, a foam, a mousse, a spray, and the like.
  • Other ingredients may also be included that may be selected depending on the intended use of the carrier and / or combination.
  • Additional ingredients include water-soluble colorants (such as FD & C Blue # 1); Oil-soluble colorants (such as D & C Green # 6); Water-soluble sunscreens (such as Eusolex 232); Oil-soluble sunscreens (such as octyl methoxycinnamate); Particulate sunscreens (such as zinc oxide); Antioxidants (such as BHT); Chelating agents (such as disodium EDTA); Emulsion stabilizers (such as carbomers); Preservatives (such as methyl parabens); Flavoring (such as pinene); Flavorings (such as sorbitol); Humectant (such as glycerin); Waterproofing agents (such as PVP / eicosene copolymers); Water-soluble film forming agents (such as hydroxypropyl methylcellulose); Oil-soluble film-forming agents (such as hydrogenated C-9 resins); Cationic acid polymers (such as polyquaternium 10); Anionic polymers (such as xanthan
  • 'Functional food' or 'functional food' in the present invention means a food that improves the functionality of the general food by adding the extract of the tea tree according to the present invention, preferably the extract of the new tea tree (Changwon No. 3) to the general food do.
  • Functionality can be roughly divided into physical properties and physiological functions.
  • the physical properties and physiological functions of general foods will be improved, and the present invention provides a food product of such an improved function as a comprehensive 'functional food.
  • Health functional food "or" functional food (health functional food) ".
  • health functional food refers to a food manufactured and processed using raw materials or ingredients having functional properties useful for the human body according to the Health Functional Food Act No. 10213, and nutrients for the structure and function of the human body. It is meant to be consumed for the purpose of regulating or obtaining a useful effect for health use such as physiological action.
  • the health functional food containing the extract of the tea tree according to the present invention preferably the extract of the new tea tree (Changwon No. 3), will give a synergistic effect to the main effect within the scope of not impairing the main effect of the present invention.
  • other ingredients that may be present.
  • it may further include additives such as perfumes, pigments, fungicides, antioxidants, preservatives, moisturizers, thickeners, inorganic salts, emulsifiers and synthetic polymer materials to improve physical properties.
  • supplementary ingredients such as water soluble vitamins, oil soluble vitamins, polymer peptides, polymer polysaccharides and seaweed extract may be further included.
  • compositions of the present invention can be used in the form of additives for other foods.
  • the formulation of the functional food containing the extract of the tea tree, preferably the extract of tea tree (Changwon No. 3) according to the present invention is not particularly limited, for example, tablets, granules, drinks, beverages, solutions, emulsions, It may be formulated in various forms, such as viscous mixtures, tablets, powders, liquids, teas, and the like, and is preferably a functional tea composition.
  • the health functional food administration may be administered by a variety of methods, such as simple drinking, injection, spray or squeeze method.
  • the cropping method and cultivation management were performed according to the Rural Development Administration Standard Agricultural Exchange Number.
  • the hybrid breeding is first selected from the gene source containing a high content of 3 " -O- Me-EGCG, a specific functional ingredient among domestic native tea tree gene sources, the gene After mating the originals to obtain lively progeny, they were grown, but elites containing high content of 3 " -O- Me-EGCG were grown.
  • sprouting time and leaf properties (leaf shape, parenting, leaf color, leaf width, leaf length, leaf area, chlorophyll content, etc.);
  • eggplant characteristics soot, water washing, eggplant thickness and eggplant density
  • the growth characteristics test more specifically, in the first tea period (April 24 to May 5) at the time of opening 70% of the infants, a grid of 20 cm horizontal and vertical on the tea tree and 1 in the lattice All shoots were harvested up to 3 cores of the core, and the mean values of the growth indicators, including fertility, leaf length, leaf width, renal intestine and renal middle weight, were measured according to the International Plant Genetic Standards of Korea's National Species. Fertility was compared by examining the germination of the germination which is 70% of the total sprouts. Kidneys measured the stem length from the base of the shoot to the uppermost lobe. The infant weight was evaluated as the weight of 100 buds. Leaf area, leaf width, and leaf area were irradiated to the third leaf from the collected kidney, and leaf area was measured using a leaf area meter (LI-3100 Area Meter, LI-COR. Inc., Japan).
  • Table 1 below shows the cropping characteristics, which are the selection criteria for new varieties of tea tree.
  • Table 2 shows the chemical component characteristics for the evaluation of chemical components, which is a selection criteria of new tea varieties.
  • Component Content Characteristics Content range 3 -O- Me-EGCG (mg / g) 4.00 or more Total amount of amino acid (TFAA) (% by weight) 3.50 or more Deanine content (% by weight) 2.20 or more Nitrogen content (% by weight) 6.00 or more Caffeine Content (mg / g) 23.5 or less Total catechin (mg / g) 100.0 or less
  • the "SPAD” value described herein is a value measured by a non-destructive method of predicting chlorophyll content or nitrogen content of a leaf by measuring the greenness of the leaf using a chlorophyll meter (SPAD-502, Minolta, Japan). Means.
  • “SPAD (Soil & Plant analyzer development)” is a measuring instrument developed by the Soil & Plant Analyzer Development Project (SPAD) in the Ministry of Agriculture, Forestry and Fisheries. The principle of this instrument is to generate light in the chlorophyll-sensitive wavelength band of 650nm and insensitive wavelength band of 940nm using light emitting diodes, and then pass the light through a 2 * 3mm window and measure 1.2mm in thickness. The intensity of light passing through the leaves of plants within is measured with a silicon photodiode and the chlorophyll content is expressed as a value between -9.9 and 99.9 using the difference between the two wavelength bands.
  • the NIR analyzer (NIRs-XDS, Foss) was used to measure the near-infrared absorption spectra (400-2500nm) for each sample, and the individual contents were calculated.
  • Table 3 below shows the growth characteristics that are the selection criteria of new varieties of tea tree.
  • Jangwon No. 3 a new type of tea tree selected by the above breeding method, was collected from the first to third leaves of the new shoots based on the 70% of the first five-leaf openings during the first water vehicle (early May). Steam was passed for 40 seconds in the hot air, dried in an 80 °C dryer, powdered by a grinder, and then separated into a 60 mesh sieve and powdered. 100 g of a new cultivated tea tree (Changwon No. 3) was refluxed by adding 1 L of 70% (v / v) aqueous solution of ethanol (v / v) + 30% (v / v) of distilled water). Extraction, filtration and concentration under reduced pressure at 40 ⁇ 45 °C finally secured 19.2g of the dried extract (Example 1) of the tea varieties (Changwon No. 3) leaves.
  • Example 1 Except for using a new tea tree varieties Yabugida in Example 1 instead of Yabugida varieties introduced in Example 1, was prepared in the same manner as in Example 1 to finally secure 17.5g of the dried extract of Yabugida leaves.
  • Example 1 Except for using a new tea varieties Kanayamidori instead of a new tea tree (Changwon No. 3) in Example 1 was prepared in the same manner as in Example 1 to finally secure 17.1g of the dried extract of Kanayamidori leaves.
  • Example 3 Except for using a new tea tree (Changwon No. 3) in Example 1, except that the general tea tree introduced varieties Yutagami-dori, prepared in the same manner as in Example 1 finally secured 18.3g of the dried extract of the leaves of Yutagami-dori It was.
  • Example 10 Except for fermented tea, oolong tea (semi-fermented tea), and black tea (fermented tea) in the same manner as in Example 2, except that Yabugida, a general tea tree introduced variety, was used in place of the new tea tree varieties (Changwon No. 3). And post-fermented tea was prepared (see Formulation Example 10 below).
  • Example 10 Except for fermented tea, oolong tea (semi-fermented tea), and black tea (fermented tea) in the same manner as in Example 2, except that Okumidori, a general tea tree introduced variety, was used in place of the new tea tree varieties (Changwon No. 3). ) And post-fermented tea were prepared (see Formulation Example 10 below).
  • Extract of the new tea varieties (Changwon No. 3) leaf prepared in Example 1, the extract of Yabugida leaf prepared in Comparative Example 1, the extract of the Kanayami-dori leaf prepared in Comparative Example 2, the yutagami-dori prepared in Comparative Example 3
  • the catechin and caffeine components of the extracts of the leaves were analyzed.
  • each of the extracts were dissolved in 50% methanol to make a 10,000 ppm solution, followed by component analysis using High-Performance Liquid Chromatography (HPLC) (Waters). Waters, 2996 PDA detector).
  • HPLC High-Performance Liquid Chromatography
  • the stationary phase was Mightysil RP-18 GP 250 * 4.6 (5 ⁇ m) column of Kanto Chemical, and the mobile phase was used in the composition ratio shown in Table 5. If necessary, catechin and caffeine component analysis can be performed by near infrared spectroscopy.
  • the total content of catechin was 41.1% by weight in the extract of the new type of tea tree (Changwon No. 3) leaves, extract of Yabugida leaf (28.1% by weight), Ghana, the general tea tree introduced varieties It was higher than the extract of Yami-dori leaves (26.7 wt%) and the extract of Yutagami-dori leaves (26.4 wt%).
  • tea tree new varieties (manor third) of the leaf extract is a catechin epi go -3- O - (3- O - methyl) gallate (epigallocatechin-3-O- (3 -O-methyl) gallate; EGCG3 "Me; 3 ” -O- Me-EGCG) was found to be present in an amount of 2.5% by weight, which is more than 10 times higher than that of general tea plants.
  • the extracts derived from the new tea tree are more antioxidant and It can be expected that the aging and anti-inflammatory effects will be better.
  • the extract of the new tea tree (Changwon No. 3) leaf of Example 2 showed a higher total content of catechin than Yabugida extract of 4.
  • the total content of the catechin is gallic acid (GA), gallocatechin (gallocatechin, GC), epigallocatechin (epigallocatechin, EGC), catechin (catechin, C), epigallocatechin gallate (epigallocatechin gallate) , EGCG), epicatechin (epicatechin, EC), Gallo catechin gallate (gallocatechin gallate, GCG), to epi-catechins go -3- O - (3- O - methyl) gallate (epigallocatechin-3- O - (3- O -methyl) gallate; EGCG3 "Me;3" -O- Me-EGCG) and epicatechin gallate (ECG).
  • the content of 3 ” -O- Me-EGCG) of the extracts of the tea varieties (Changwon No. 3) leaves of Example 2 was 4.7 mg ⁇ g in green tea, oolong tea (semi-fermented tea) and black tea (fermented tea), respectively. 1, it is shown with 3.6mg ⁇ g -1, 1.94mg ⁇ g -1. That is, 3 ” -O- Me-EGCG contained in the leaves of the new tea tree (Changwon No. 3) is transformed into components such as deoflavin and deorubidine, which are catechin polymers by oxidation during processing like other catechin compounds. It was confirmed that the content of 3 ” -O- Me-EGCG contained in the tea stream was reduced.
  • Test substance IC 50 (ppm) AsA (Vitamin C) 7.1 Tea tree new varieties (Jangwon No. 3) extract (Example 1) 10.2 Yabugida Extract (Comparative Example 1) 35.1 Kanaya Midori Extract (Comparative Example 2) 31.5 Yutagami-dori Extract (Comparative Example 3) 37.7
  • the extract (Example 1) of a new type of tea tree (Changwon No. 3) showed a similar antioxidant effect as compared to the ascorbic acid, an antioxidant used as a positive control. Compared to Gan, Kanaya Midori and Yutagamidori extracts, it showed significantly higher antioxidant efficacy.
  • the new tea tree (Changwon 3) In order to confirm the superoxide anion scavenging activity of the new extract of Tea tree (Changwon 3) and the Yabugida extract (Comparative Example 1), the new tea tree (Changwon 3) at concentrations of 10 ⁇ M and 20 ⁇ M Superoxide anion scavenging activity of the extract, Yabugida extract and ascorbic acid (Ascorbic acid, AsA, Vitamin C) as a positive control was measured by ESR spectrophotometer.
  • the DMPO-OOH signal generated without the treatment of antioxidants can be strongly erased, and when calculated by the number of mol, the extract of new tea tree (Changwon No. 3) than the rate of DMPO reacting with superoxide anion (or 3 " O- Me-EGCG) reacted with superoxide anion about 10,000 times higher.
  • the superoxide anion scavenging activity of the extract of new tea tree was higher than that of AsA, which is the major functional ingredient of EGCG (epigallocatechin gallate) and 3 " -O -Me This may be due to ortho-trihydroxy in the gallate group and the B ring.
  • the new extract of tea tree (Changwon No. 3) showed higher superoxide anion scavenging activity than Yabugida extract, not only by the catechin component but also by the catechin component 3 " -O- Me-EGCG. We believe this is due to a synergistic effect.
  • the new extract of tea tree (Changwon No. 3) was higher in scavenging activity at a concentration of 10 ⁇ M or 25 ⁇ M than Yabugida extract.
  • the scavenging activity between the two extracts was not significantly different, but the new extract of tea tree (Changwon No. 3) showed about 5 times higher hydroxyl radical scavenging activity than AsA.
  • the collagenase production inhibitory ability of each extract prepared in Example 1 and Comparative Examples 1 to 3 was measured by comparing with Tocopherol.
  • Tocopherol is a representative antioxidant that is known to have a function of preventing skin aging by regenerating epidermal cells of the skin.
  • the test was performed by placing human fibroblasts at 5,000 cells / well in a 96-well microtiter plate containing Dulbecco's Modified Eagle's Media (DMEM) medium containing 2.5% fetal calf serum. Incubate until growth. After culturing in serum-free DMEM medium for 24 hours, the extracts of Preparation Example 1 and Comparative Examples 1 to 3 dissolved in serum-free DMEM medium were treated at 50 ppm concentration and tocopherol at 1x10 -4 molar concentration for 24 hours. Cell culture was collected.
  • DMEM Dulbecco's Modified Eagle's Media
  • the collected cell culture solution was measured for the degree of collagenase production using a commercially available collagenase measuring instrument (Amersham Pharmacia, USA). First, the collected cell culture was placed in a 96-well plate uniformly coated with primary collagenase antibody, and the antigen-antibody reaction was performed in a thermostat for 3 hours.
  • the chromophore-conjugated secondary collagen antibody was placed in a 96-well plate and reacted again for 15 minutes. After 15 minutes, the coloring stimulant was added, causing color development at room temperature for 15 minutes, and 1M sulfuric acid was added again to stop the reaction (color development). The color of the reaction solution was yellow and the degree of yellow color was different according to the progress of the reaction.
  • the absorbance of the yellowish 96-well plate (96-well plate) was measured at 405 nm using an absorbance meter, and the degree of synthesis of collagenase was calculated by Equation 1 below.
  • the reaction absorbance of the collected cell culture medium of the group not treated with the composition was used as a control. That is, the expression level of collagenase in the non-treated group was set to 100, and the expression level of collagenase in the group treated with the test substance was calculated, and the results are shown in Table 9 below.
  • Test substance Collagenase expression level (%) Untreated group 100 Tocopherol 63 Tea tree new varieties (Jangwon No. 3) extract (Example 1) 51 Yabugida Extract (Comparative Example 1) 69 Kanaya Midori Extract (Comparative Example 2) 74 Yutagami-dori Extract (Comparative Example 3) 76
  • Example 3 is more to the expression of collagenase than the general tea tree introduced varieties Yabugida, Kanayami-dori and Yutagami-dori extracts of Comparative Examples 1 to 3 It was confirmed that the effect of inhibiting collagen breakdown in the skin by effectively inhibiting the skin elasticity enhancing effect and wrinkle reduction effect is excellent.
  • the skin anti-inflammatory effect of each extract prepared in Example 1 and Comparative Examples 1 to 3 was evaluated as a production inhibitory effect of prostaglandins.
  • the anti-inflammatory effect was measured in macrophages using each of the extracts.
  • aspirin was added to macrophages taken from the abdominal cavity of mice to a final concentration of 500 M, thereby irreversibly inhibiting cyclooxygenase (COX) activity remaining in the cells.
  • COX cyclooxygenase
  • the suspension was added to each well of a 96-well cell culture tube and incubated for 2 hours in an incubator at 37 ° C. with 5% CO 2 to attach macrophages to the container surface.
  • the attached macrophages were then washed three times with PBS and used for the anti-inflammatory effect test.
  • Example 1 and Comparative Example 1 100 ⁇ l of each extract prepared in ⁇ 3 was used to quantify free prostaglandins using enzyme-linked immunosorbent assay (ELISA). At this time, the prostaglandin production inhibitory activity (%) of each extract prepared in Example 1 and Comparative Examples 1 to 3 is shown in Table 10 below.
  • Test substance Prostaglandin inhibitory ability (%) Untreated group (NT) 0 Control group (aspirin treated group) 58.6 Tea tree new varieties (Jangwon No. 3) extract (Example 1) 56.9 Yabugida Extract (Comparative Example 1) 37.5 Kanaya Midori Extract (Comparative Example 2) 27.4 Yutagami-dori Extract (Comparative Example 3) 33.8
  • the extract (Example 1) of a new type of tea tree (Changwon No. 3) was found to have a very high inhibitory effect on the production of prostaglandins as in the control group treated with aspirin, and the general tea tree of Comparative Examples 1 to 3 Compared with the introduced varieties Yabugida, Kanayamidori and Yutagamidori extracts, the prostaglandin production inhibitory effect was remarkably high.
  • the extract of tea tree new varieties (Changwon No. 3) according to the present invention and the composition comprising the same has an anti-inflammatory effect by inhibiting the expression of prostaglandin, a skin inflammation factor, and further improves skin acne and skin allergy by alleviating skin troubles.
  • the composition comprising the same has an anti-inflammatory effect by inhibiting the expression of prostaglandin, a skin inflammation factor, and further improves skin acne and skin allergy by alleviating skin troubles.
  • Example 1 Each extract prepared in Example 1 and Comparative Examples 1 to 3 was treated in each well according to the concentrations of Table 6, followed by reaction for 30 minutes, followed by PGSA (10 ⁇ g / ml), PGSA (50 ⁇ g / ml), and PGSA. (50 ⁇ g / ml) + LPS (1 ⁇ g / ml) were treated respectively.
  • PGSA peptidoglycan from S.
  • peptidoglycan is a peptidoglycan (peptidoglycan) extracted from Staphylococcus aureus, a major component of the cell wall of Gram-positive bacteria and bacterial membrane components are known to cause inflammation, In particular, in staphylococci, about 90% of patients with atopic dermatitis have been reported to cause secondary infection. After incubation for 24 hours at 37 °C, 5% CO 2 incubator, the culture medium was taken and subjected to ELISA for interleukin-8, the results are shown in Table 11 below. ELISA used the experimental method of the manufacturer (BD science).
  • Test substance IL-8 secretion (pg / ml) Untreated group (NT) 935.12 10 ⁇ g / ml PGSA 4725.64 PGSA 10 ⁇ g / ml + New Tea Tree (Changwon No. 3) Extract (Example 1) 25ppm 1503.29 PGSA 10 ⁇ g / ml + New Tea Tree (Changwon No.
  • the extract (Example 1) of a new tea tree (Changwon No. 3) was found to have a very high effect of inhibiting the secretion of IL-8 increased by PGSA, an inflammation-inducing stimulus, Comparative Examples 1 to 3 It was found that significantly reduced and inhibited IL-8 secretion compared to the extracts of Yabugida, Kanayami-dori and Yutagami-dori, which are introduced from the tea strains.
  • the extract of tea tree new varieties (Changwon No. 3) according to the present invention and the composition comprising the same has an anti-inflammatory effect by inhibiting the secretion of the skin inflammation-induced stimulus IL-8, and further alleviate the skin trouble to skin acne and skin allergy It could be confirmed that can be improved.
  • Extract of tea tree (Changwon No. 3) leaf (hereinafter referred to as tea tree new breed (Changwon No. 3) extract), or 3 " -O- Me-EGCG isolated from said extract, cancer cell line lung cancer cell line (A549), kidney cancer Cell lines (ACHN), colon cancer cell lines (HCT15), prostate cancer cell lines (LNCaP) and breast cancer cell lines (MCF-7) were treated and then incubated for 36 hours in a 37 ° C, 5% CO 2 incubator. After cultivation, the extract of tea tree varieties (Changwon No. 3), or 3 " -O- Me-EGCG on the cell line was confirmed by MTT assay, but negative control treated with 0.1% DMSO. Relative cancer cell proliferation was measured as a reference.
  • - O handling -Me-EGCG in a concentration of 50 ⁇ g ⁇ mL -1, 100 ⁇ g ⁇ mL -1 and 200 ⁇ g ⁇ mL -1 In this case, the proliferation rate of prostate cancer cell lines was about 46%, 37%, and 20%, respectively, and the cancer cell proliferation inhibitory effect was high, and the breast cancer cell line (MCF-7) was also derived from the new tea tree (Changwon 3) extract under the same conditions.
  • MCF-7 breast cancer cell line
  • Lung cancer cell line tea new varieties (manor No. 3) to (A549) extracts from 3 "- in case of processing the O -Me-EGCG in a concentration of 50 ⁇ g ⁇ mL -1, 100 ⁇ g ⁇ mL -1 and 200 ⁇ g ⁇ mL -1 , Cancer cell proliferation was about 41%, 20% and 16%, respectively, lung cancer cell line (A549) showed higher cancer cell proliferation inhibitory effect than prostate cancer cell line (LNCaP) and breast cancer cell line (MCF-7).
  • Green tea (fermented tea), oolong tea (semi-fermented tea), black tea (fermented tea), or black tea (post-fermented tea) has different characteristics such as shape, color, aroma, color search, and taste.
  • Semi-fermented tea), black tea (fermented tea), or black tea (post-fermented tea) changes in palatability, color, taste, etc. according to the fermentation progress, and the contained ingredients also change.
  • extracts of the new tea tree varieties (Changwon No.
  • Example 3 3) of Example 2, Yabugida (Japanese varieties) extract of Comparative Example 4, and Comparative Examples For Okumidori (Japanese varieties) extract of 5, appearance evaluation (shape, color; perfect score of 40 points) and quality evaluation (fragrance, search, taste; perfect score of 60 points) were carried out to investigate palatability and functionality as tea. ) was performed.
  • the new varieties of tea tree (Changwon No. 3) had higher palatability in both semi-fermented tea, fermented tea and post-fermented tea than Yabugida and Okumi-dori. It appeared to have, and has excellent characteristics in the production of various kinds of tea, and it was evaluated that the utilization was very high.
  • Nutritional cream was prepared in a conventional manner according to the composition described in Table 15 (unit: wt%).
  • the pack was prepared by the conventional method according to the composition described in Table 17 (unit: wt%).
  • Ointment was prepared in a conventional manner according to the composition described in Table 18 (unit: wt%).
  • Extract of new tea tree (Changwon No. 3) (Example 1) 80 mg, vitamin E 9 mg, vitamin C 9 mg, palm oil 2 mg, vegetable hardened oil 8 mg, beeswax 4 mg and lecithin 9 mg were mixed and mixed according to a conventional method to fill soft capsules. A liquid was prepared. 400 mg per capsule was filled to prepare a soft capsule. In addition, a soft capsule sheet was prepared at a ratio of 66 parts by weight of gelatin, 24 parts by weight of glycerine, and 10 parts by weight of sorbitol solution and filled with the filler to prepare a soft capsule containing 400 mg of the composition according to the present invention.
  • Extract of tea tree (Changwon No. 3) (Example 1) 80 mg, vitamin E 9 mg, vitamin C 9 mg, galactooligosaccharide 200 mg, lactose 60 mg and maltose 140 mg were mixed and granulated using a fluidized bed dryer and then sugar ester (sugar ester) 6 mg was added. Tablets were prepared by compression of 504 mg of these compositions in a conventional manner.
  • Extract of a new tea tree (Changwon No. 3) (Example 1) 80 mg, vitamin E 9 mg, vitamin C 9 mg, glucose 10 g, citric acid 0.6 g, and 25 g of liquid oligosaccharides were mixed and 300 ml of purified water was added to each bottle 200 ml. Filled very hard. After filling the bottle sterilized for 4 to 5 seconds at 130 °C to prepare a beverage.
  • Extract of tea tree (Changwon No. 3) (Example 1) 80 mg, vitamin E 9 mg, vitamin C 9 mg, 250 g of anhydrous glucose, and 550 mg of starch were mixed and formed into granules using a fluidized bed granulator, and then filled into sachets. It was prepared by.
  • the tea leaf temperature was maintained at 90 ° C. for 30 seconds using a boiler-operated steamer. . After drying enough to have a water content of 6% or less, and milled to a particle size of 0.5 ⁇ 4mm using a grinding machine was prepared as 1.0g tea bag.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Birds (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne une composition contenant un extrait de Camellia sinensis, de préférence un extrait d'une nouvelle variété de Camellia sinensis (numéro 3 de Jangwon), et plus particulièrement, une composition contenant, en tant que principe actif, un extrait de Camellia sinensis présentant une teneur élevée en épigallocatéchine-3-O-(3-O-méthyl)gallate (EGCG3"Me ; 3"-O-Me-EGCG). Une composition selon la présente invention contenant, en tant que principe actif, un extrait de Camellia sinensis présentant une teneur élevée en épigallocatéchine-3-O-(3-O-méthyl)gallate a un effet antioxydant dû à l'élimination et à la suppression de radicaux libres, a un effet anti-âge sur la peau en raison d'une excellente aptitude à inhiber la formation de collagénase, a un effet anti-inflammatoire dû à l'inhibition de l'expression et de la sécrétion de facteurs inflammatoires, tels que la prostaglandine et l'IL-8 et analogues, dans des cellules de la peau, et a un excellent effet anticancéreux vis-à-vis des lignées de cellules cancéreuses dérivées de divers tissus.
PCT/KR2018/005605 2017-05-16 2018-05-16 Composition contenant un extrait de camellia sinensis WO2018212588A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201880032982.9A CN111050783A (zh) 2017-05-16 2018-05-16 含茶树提取物的组合物
MYPI2019006749A MY197901A (en) 2017-05-16 2018-05-16 Composition containing camellia sinensis extract

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2017-0060641 2017-05-16
KR1020170060641A KR102428987B1 (ko) 2017-05-16 2017-05-16 차나무의 추출물을 함유하는 조성물

Publications (1)

Publication Number Publication Date
WO2018212588A1 true WO2018212588A1 (fr) 2018-11-22

Family

ID=64274183

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/005605 WO2018212588A1 (fr) 2017-05-16 2018-05-16 Composition contenant un extrait de camellia sinensis

Country Status (4)

Country Link
KR (1) KR102428987B1 (fr)
CN (1) CN111050783A (fr)
MY (1) MY197901A (fr)
WO (1) WO2018212588A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3116438B1 (fr) 2020-11-23 2022-10-14 Isp Investments Llc Procede d’obtention d’extraits aqueux de feuilles de thes, compositions comprenant de tels extraits et leurs utilisations cosmetiques
CN112545909B (zh) * 2020-12-14 2022-06-21 湖南农业大学 一种茶黄素组合物及其应用
FR3125425A1 (fr) 2021-07-22 2023-01-27 Isp Investments Llc Extrait de feuilles de the noir, compositions le comprenant et ses utilisations cosmetiques
KR102462676B1 (ko) 2021-10-05 2022-11-03 권휘 차종의 외피를 활용한 차 제다 방법
KR20230136988A (ko) 2022-03-21 2023-10-04 영남대학교 산학협력단 에피갈로카테킨 갈레이트를 유효성분으로 포함하는 테트라넥틴 활성 억제용 조성물
KR20230170163A (ko) 2022-06-09 2023-12-19 대한민국(농촌진흥청장) 신품종 차나무 및 이의 육종방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015199169A1 (fr) * 2014-06-27 2015-12-30 国立大学法人九州大学 Procédé d'amélioration de la fonction de la catéchine
KR20160127860A (ko) * 2015-04-27 2016-11-07 강원대학교산학협력단 메틸화카테킨을 유효성분으로 함유하는 항피부노화용 조성물
KR101722427B1 (ko) * 2015-04-27 2017-04-04 강원대학교산학협력단 메틸화카테킨을 유효성분으로 함유하는 암세포의 성장억제용 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2275463T3 (es) * 1999-08-16 2007-06-16 Dsm Ip Assets B.V. Proceso para la produccion de galato de epigalocatequina.
EP1157693A1 (fr) * 2000-05-12 2001-11-28 National Agricultural Research Organisation (NARO) Utilisation de l'epigallocatechin 3-o-(3-o-methyl) gallate et/ou l'epigallocatechin 3-o-(4-o-methyl) gallate pour le traitement de l'allergie et/ou l'inflammation
JP4742752B2 (ja) 2005-08-30 2011-08-10 独立行政法人農業・食品産業技術総合研究機構 飲料の製造方法
CN1951383A (zh) * 2005-10-17 2007-04-25 美国安乃仁生命科技公司 稳定化含儿茶素医药及化妆品用组合物
KR101213200B1 (ko) * 2009-08-24 2012-12-18 주식회사 장원 신품종 차나무의 육종방법
KR20160069738A (ko) * 2014-12-09 2016-06-17 (주)아모레퍼시픽 메틸화된 카테킨을 유효성분으로 함유하는 ercc8 유전자 활성화용 조성물
KR20160069737A (ko) * 2014-12-09 2016-06-17 (주)아모레퍼시픽 메틸화된 카테킨을 유효성분으로 함유하는 Sirt-1 유전자 활성화용 조성물
CN104820059B (zh) * 2015-04-22 2016-07-06 湖南农业大学 一种快速筛选含有EGCG3"Me茶树资源的方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015199169A1 (fr) * 2014-06-27 2015-12-30 国立大学法人九州大学 Procédé d'amélioration de la fonction de la catéchine
KR20160127860A (ko) * 2015-04-27 2016-11-07 강원대학교산학협력단 메틸화카테킨을 유효성분으로 함유하는 항피부노화용 조성물
KR101722427B1 (ko) * 2015-04-27 2017-04-04 강원대학교산학협력단 메틸화카테킨을 유효성분으로 함유하는 암세포의 성장억제용 조성물

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MAEDA-YAMAMOTO, MARI: "Changes in epigallocatechin-3-0-(3-0-methyl) gallate and strictinin contents of tea (Camellia sinensis L.) cultivar ''Benifuki'' in various degrees of maturity and leaf order", FOOD SCIENCE AND TECHNOLOGY RESEARCH, vol. 10, no. 2, May 2004 (2004-05-01), pages 186 - 190, XP055612773 *
ZHANG, XIN ET AL: "Antioxidant and hepatoprotective effect of (-)-epigallo catechin 3-0-(3-0-methyl) gallate (EGCG3'' Me) from Chinese oolong tea", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, vol. 62, no. 41, 2014, pages 10046 - 10054, XP055612775 *

Also Published As

Publication number Publication date
KR102428987B1 (ko) 2022-08-04
CN111050783A (zh) 2020-04-21
KR20180125828A (ko) 2018-11-26
MY197901A (en) 2023-07-24

Similar Documents

Publication Publication Date Title
WO2018212588A1 (fr) Composition contenant un extrait de camellia sinensis
WO2021137677A1 (fr) Composition contenant un extrait de plante
US20100015071A1 (en) Compositions for Improving Skin Conditions Comprising Alpha-Bisabolol as an Active Ingredient
KR102152750B1 (ko) 장미 추출물을 포함하는 조성물
WO2012169664A1 (fr) Agent dermique externe et aliment fonctionnel contenant un produit cultivé à partir de tissu de placenta de rose ou extrait de celui-ci
WO2017146414A1 (fr) Composition pour l'hydratation de la peau et atténuation des rides cutanées, contenant du α-terpinéol en tant que substance active
KR101664025B1 (ko) 천연 식물 추출물을 함유하는 화장료 조성물
KR100785505B1 (ko) 항산화효과와 미백효과를 갖는 한방 약재 추출물과 그추출물의 제조방법 및 이를 포함하는 화장료 조성물
WO2018080039A1 (fr) Composition destinée à prévenir la chute des cheveux ou à améliorer la croissance des cheveux, contenant un extrait de feuilles de soja de couleur jaune
WO2022085858A1 (fr) Composition pour le blanchiment de la peau ou l'amélioration des rides comprenant un extrait de dendropanax morbiferus
WO2018097388A1 (fr) Composition pour le blanchiment de la peau, l'atténuation des rides, l'antioxydation et la protection contre la lumière ultraviolette, contenant un extrait de graine de jujube comme principe actif
Puertas-Mejía et al. Screening of UVA/UVB absorption and in vitro antioxidant capacity of Bejaria aestuans, Cavendishia pubescens and Cavendishia bracteata leaf extracts
KR20200138003A (ko) 인디안구스베리 추출물과 새싹보리 추출물의 복합물(ib복합물)을 유효성분으로 포함하는 비만 및/또는 당뇨를 동반하는 대사증후군의 예방, 개선 치료용 조성물
KR20180043567A (ko) 니파야자 꽃대를 이용한 화장료 조성물
KR101512811B1 (ko) 붉은호장근 추출물을 포함하는 미백 화장료 조성물
KR101889331B1 (ko) 섬오가피나무 줄기 추출물, 이의 분획물 또는 이로부터 분리된 화합물을 유효성분으로 함유하는 항산화, 항염증 또는 항균용 조성물
KR102176618B1 (ko) 옥촉서예 추출물을 유효성분으로 함유하는 조성물
KR20220163542A (ko) 레몬머틀 및 꽃송이 버섯의 혼합추출물을 포함하는 항산화, 항염 및 안티 폴루션용 조성물
KR100917281B1 (ko) 사랑초 추출물을 유효성분으로 포함하는 피부 미백 개선제
KR101797843B1 (ko) 섬오가피나무 줄기 추출물, 이의 분획물 또는 이로부터 분리된 화합물을 유효성분으로 함유하는 항염증 또는 항균용 조성물
WO2023128630A1 (fr) Composition cosmétique améliorant la peau comprenant un extrait d'elaeocarpus sylvestris var. ellipticus (thunb.) hara
WO2017003190A1 (fr) Composition cosmétique éclaircissante comprenant un extrait de racine de caragana sinica
KR20190124351A (ko) 민물김 추출물을 유효성분으로 포함하는 피부 미백용 조성물
KR101434300B1 (ko) 새머루 또는 낙지다리 추출물을 포함하는 미백 화장료 조성물
KR102419455B1 (ko) 주걱비름 캘러스 추출물을 유효성분으로 하는 화장료 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18802462

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18802462

Country of ref document: EP

Kind code of ref document: A1